*LUCENTIS 0.2 mg is indicated in preterm infants for:1
The treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.
†LUCENTIS 0.5 mg is indicated in adults for:1
The treatment of neovascular (wet) age-related macular degeneration (AMD)
The treatment of visual impairment due to diabetic macular oedema (DMO)
The treatment of proliferative diabetic retinopathy (PDR)The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
The treatment of visual impairment due to choroidal neovascularisation (CNV).
‡Once maximum VA is achieved and/or disease activity is stable.
DMO, diabetic macular oedema; CNV, choroidal neovascularisation; HCP, healthcare professional; PDR, proliferative diabetic retinopathy; proliferative diabetic retinopathy; ROP, retinopathy of prematurity; RVO, retinal vein occlusion; T&E, treat & extend;‡ VEGF, vascular endothelial growth factor; wAMD, wet age-related macular degeneration.
- Lucentis (ranibizumab) Summary of Product Characteristics, July 2020.
- Lucentis® SmPC history.
- Dorairaj E, et al. Ranibizumab in diabetic macular oedema: 2 year audit data. Presented at ESCRS 2017, Maastricht, The Netherlands.
- Prakash, P, et al. To determine the efficacy of treatment of Ranibizumab over a period of 5 years in patients with DMO at PAH, Harlow, presented at Royal College of Ophthalmology congress 2021.
- Mitchell P, et al. Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: Results from the real-world global LUMINOUS study. PLoS One. 2020;15(6):32492069.